首页 › 基金 › Frazier Life Sciences Management, L.P. › TRVI

Frazier Life Sciences Management, L.P. 对 TRVI 的持仓历史

TREVI THERAPEUTICS INC · 医疗保健

Frazier Life Sciences Management, L.P. 在 Q2 2026 的 13F 申报中披露持有 TRVI(TREVI THERAPEUTICS INC)9,939,447 股,市值约 US$185.4M,约占其申报组合的 4.04%,在其申报持仓中市值排名第 6 位。 Frazier Life Sciences Management, L.P. 最近 12 个申报季度中有 12 个季度披露了 TRVI 持仓,最早可追溯至 Q3 2023。

最新持仓 (Q2 2026)9.94M 股
申报持仓市值$185.37M
组合权重4.04%
首次申报Q3 2023
最近变动持有
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

Frazier Life Sciences Management, L.P. 对 TRVI 的持仓演变

Frazier Life Sciences Management, L.P. 于 Q3 2023 首次披露 TRVI 持仓:6,881,090 股(约 US$15.0M)。 该持仓在 Q2 2026 达到峰值 9,939,447 股,市值约 US$185.4M。 在 12 次申报中,Frazier Life Sciences Management, L.P. 2 次增持、2 次减持、7 次保持不变。 最近一期申报(Q2 2026)显示持股 9,939,447 股、市值约 US$185.4M。 持仓曾出现大幅变动:Q4 2024 增持约 44% (随后一个季度股价上涨 53%)。

逐季持仓明细

季度股数金额变化
Q3 2023 6.88M $15.00M 新进
Q4 2023 7.38M $9.89M 增持
Q1 2024 7.38M $25.46M 持有
Q2 2024 7.38M $22.00M 持有
Q3 2024 7.38M $24.65M 持有
Q4 2024 10.66M $43.94M 增持
Q1 2025 10.26M $64.53M 减持
Q2 2025 10.26M $56.12M 持有
Q3 2025 10.26M $93.87M 持有
Q4 2025 10.26M $128.45M 持有
Q1 2026 9.94M $118.58M 减持
Q2 2026 9.94M $185.37M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 TRVI 与 13F 数据

TRVI(TREVI THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 64 只申报持有 TRVI,申报仓位最大的包括:NEA Management Company, LLC (US$246.6M), Vivo Capital, LLC (US$95.0M), Vestal Point Capital, LP (US$57.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 TRVI 的基金

查看 TRVI 的全部基金持有人 →

常见问题

How long has Frazier Life Sciences Management, L.P. held TRVI?

Frazier Life Sciences Management, L.P. has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Frazier Life Sciences Management, L.P.'s current position in TRVI?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 9.94M shares of TRVI (TREVI THERAPEUTICS INC), valued at $185.37M, representing 4.04% of its reported portfolio and ranking #6.

Has Frazier Life Sciences Management, L.P. been buying or selling TRVI?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in TRVI. The position peaked in Q2 2026 at 9.94M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Vivo Capital, LLC, Vestal Point Capital, LP, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.